An analysis of 97 previously diagnosed de novo adult acute erythroid leukemia patients following the 2016 revision to World Health Organization classification

BMC Cancer

Research Article

Shuning Wei¹  Yuntao Liu¹  Benfa Gong¹  Jianxiang Wang¹  Ying Wang¹  Bingcheng Liu¹  Hui Wei¹  Xiaoyuan Gong¹  Shaowei Qiu¹  Chunlin Zhou¹  Guangji Zhang¹  Kaiqi Liu¹  Yingchang Mi¹  Dong Lin¹  Erlie Jiang²  Sizhou Feng²  Mingzhe Han² 

[1] Department of Leukemia Therapy, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College (CAMS & PUMC), 288 Nanjing Road, 300020, Tianjin, People’s Republic of China;Department of Stem Cell Transplantation, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China;

关键词: Acute myeloid leukemia;    Acute erythroid leukemia;    Myelodyspalstic syndrome;    Cytogenetics;   

DOI  :  10.1186/s12885-017-3528-6

 received in 2017-02-04, accepted in 2017-08-01,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundThe incidence of acute erythroid leukemia subtype (AEL) is rare, accounting for 5% of cases of acute myeloid leukemia (AML), and the outcome is dismal. However, in 2016 revision to the WHO classification, the subcategory of AEL has been removed. Myeloblasts are redefined as the percentage of total marrow cells, not non-erythroid cells. Therefore, the previously diagnosed AEL cases are currently diagnosed as AML or myelodyspalstic syndrome (MDS) according to new criteria.MethodsWe respectively reviewed cases of 97 de novo previously diagnosed AEL and all the patients were diagnosed as AML or MDS according to the new classification scheme, and then the clinical characteristics of these two subtypes were compared. Statistical analyses were performed by SPSS software version 18.0.ResultsThe median age was 37 years-old, the two-thirds of previous AEL cases were diagnosed as MDS, and there was no obvious difference between two subtypes except for male/female ratio and age. Cytogenetic, rather than MDS/AML subtypes, can better represent the prognostic factor of previously diagnosed AEL patients. When the cytogenetic risk of patients belonged to MRC intermediate category and age were below 40 years-old in previous AEL cases, the patients who received induction chemotherapy without transplantation had a similar survival compared with the patients who underwent transplantation (3-year OS: 67.2% vs 68.5%).ConclusionsCytogenetic, rather than MDS/AML subtypes, can better represent the prognostic factor of previously diagnosed AEL patients. Transplantation was a better choice for those whose cytogenetic category was unfavorable.

【 授权许可】

CC BY   
© The Author(s). 2017